Literature DB >> 3089021

Characterization of renal amyloid derived from the variable region of the lambda light chain subgroup II.

M M Picken, G Gallo, J Buxbaum, B Frangione.   

Abstract

Amyloid fibrils were extracted from the kidney of a patient (CHE) shown to have tetramers and dimers of a monoclonal lambda light chain in his serum, and whose bone marrow cells in short-term culture synthesized these forms and a smaller lambda fragment of approximately 10,000 to 12,000 daltons. Biochemical and serologic analysis of a fraction of a size (obtained from amyloid fibrils extracted from the kidney) similar to that synthesized by the bone marrow cells revealed a light chain fragment corresponding to the amino terminal end of the variable region of the lambda light chain subgroup II. The presence of similarly sized short fragments of lambda light chain in both the synthesized and deposited protein suggests that aberrant synthesis and/or proteolytic degradation may play a pathogenetic role in the process of amyloidogenesis.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3089021      PMCID: PMC1888179     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  13 in total

1.  Amyloidosis of the AL type. Clinical, morphologic and biochemical aspects of the response to therapy with alkylating agents and prednisone.

Authors:  J N Buxbaum; M E Hurley; J Chuba; T Spiro
Journal:  Am J Med       Date:  1979-11       Impact factor: 4.965

2.  A technique for the removal of pyroglutamic acid from the amino terminus of proteins using calf liver pyroglutamate amino peptidase.

Authors:  D N Podell; G N Abraham
Journal:  Biochem Biophys Res Commun       Date:  1978-03-15       Impact factor: 3.575

3.  Characterization of tissue amyloid by immunofluorescence microscopy.

Authors:  G R Gallo; H D Feiner; J V Chuba; D Beneck; P Marion; D H Cohen
Journal:  Clin Immunol Immunopathol       Date:  1986-06

4.  Chemical evidence for lambda-type amyloid fibril proteins.

Authors:  S Kimura; R Guyer; W D Terry; G G Glenner
Journal:  J Immunol       Date:  1972-10       Impact factor: 5.422

5.  Molecular weight estimation of polypeptide chains by electrophoresis in SDS-polyacrylamide gels.

Authors:  A L Shapiro; E Viñuela; J V Maizel
Journal:  Biochem Biophys Res Commun       Date:  1967-09-07       Impact factor: 3.575

6.  Structural identity of Bence Jones and amyloid fibril proteins in a patient with plasma cell dyscrasia and amyloidosis.

Authors:  W D Terry; D L Page; S Kimura; T Isobe; E F Osserman; G G Glenner
Journal:  J Clin Invest       Date:  1973-05       Impact factor: 14.808

Review 7.  The kidney in lymphoplasmacytic disorders.

Authors:  G R Gallo; H D Feiner; J N Buxbaum
Journal:  Pathol Annu       Date:  1982

8.  AA protein-related renal amyloidosis in drug addicts.

Authors:  S Menchel; D Cohen; E Gross; B Frangione; G Gallo
Journal:  Am J Pathol       Date:  1983-08       Impact factor: 4.307

9.  The characterization of soluble amyloid prepared in water.

Authors:  M Pras; M Schubert; D Zucker-Franklin; A Rimon; E C Franklin
Journal:  J Clin Invest       Date:  1968-04       Impact factor: 14.808

10.  Amyloidosis associated with renal cell carcinoma of the AA type.

Authors:  M Pras; E C Franklin; S Shibolet; B Frangione
Journal:  Am J Med       Date:  1982-09       Impact factor: 4.965

View more
  6 in total

1.  Aberrant immunoglobulin synthesis in light chain amyloidosis. Free light chain and light chain fragment production by human bone marrow cells in short-term tissue culture.

Authors:  J Buxbaum
Journal:  J Clin Invest       Date:  1986-09       Impact factor: 14.808

2.  Structure of a monoclonal kappa chain of the V kappa IV subgroup in the kidney and plasma cells in light chain deposition disease.

Authors:  M Cogné; J L Preud'homme; M Bauwens; G Touchard; P Aucouturier
Journal:  J Clin Invest       Date:  1991-06       Impact factor: 14.808

3.  Light chain deposition disease derived from the kappa I light chain subgroup. Biochemical characterization.

Authors:  M M Picken; B Frangione; B Barlogie; M Luna; G Gallo
Journal:  Am J Pathol       Date:  1989-04       Impact factor: 4.307

4.  Expanding the spectrum of monoclonal light chain deposition disease in muscle.

Authors:  Lyle W Ostrow; Andrea M Corse; Brett M Morrison; Carol A Huff; John A Carrino; Ahmet Hoke; Andrew L Mammen
Journal:  Muscle Nerve       Date:  2012-05       Impact factor: 3.217

5.  Primary amyloidosis A. Immunohistochemical and biochemical characterization.

Authors:  M M Picken; K Pelton; B Frangione; G Gallo
Journal:  Am J Pathol       Date:  1987-12       Impact factor: 4.307

6.  Complete primary sequences of two lambda immunoglobulin light chains in myelomas with nonamyloid (Randall-type) light chain deposition disease.

Authors:  C Decourt; G Touchard; J L Preud'homme; R Vidal; H Beaufils; M C Diemert; M Cogné
Journal:  Am J Pathol       Date:  1998-07       Impact factor: 4.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.